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 Obtaining reliable evidence regarding which factors cause disease or influence disease progression is 
clearly central to the development of scientific medicine. There have been many high-profile failures 
in this regard, which stretch from health-related behaviours (e.g. dietary components that 
observational epidemiology strongly suggested protected against chronic disease that failed when 
tested in large-scale randomised controlled trials), through vitamin supplement use and hormone 
replacement therapy, to a large number of drugs that failed at phase 3 trial stage1 2.Observational 
epidemiological studies are prone to confounding, reverse causation (when the disease process 
influences the exposure, rather than vice versa) and a variety of other biases1, and cellular through 
to whole-animal laboratory studies also lead to many erroneous conclusions being drawn. There are 
many strategies that need to be adopted to ameliorate this situation, with the over-arching 
philosophy being that only very rarely does any single source of evidence adequately establish the 
veracity of causal claims. Several methods should be applied to any question, each of which will have 
potential sources of bias, but the origins of, and predicted influence of, these biases should be 
unrelated to each other. With such “triangulation” of evidence, more reliable causal inference 
should be achieved3. 
A powerful component of this evidence base can be provided by the application of a methodology 
which incorporates the natural randomization inherent in the generation of genetic individuality – 
the process of Mendelian randomization4 5.  The basic principle of Mendelian randomization (MR) is 
straight-forward; it is that genetic variation generates differences between individuals that influence 
health outcomes that are not subject to the confounding or reverse-causation bias that distort 
observational findings4 5  . This process can be considered analogous to randomisation in a 
randomised controlled trial (RCT)4, and there are now many examples of its application6 . These 
range from proofs of principle (LDL cholesterol, blood pressure, obesity and smoking increase the 
risk of coronary heart disease, CHD), demonstration of factors unlikely to be causal (e.g C Reactive 
Protein in relation to CHD, diabetes and several cancers), dispelling claims of health protection (e.g. 
moderate alcohol intake is not beneficial with respect to CHD risk) and the prediction of findings 
from pharmacological RCTs of both success and failure5 6  7. 
MR studies have benefited from analytical methods adapted from “instrumental variables” 
approaches in econometrics, allowing estimation of effect sizes and their precision5. These require 
careful translation, as they can differ in magnitude from reliable estimates from other sources. For 
example, since genetic variants generally relate to life-time differences in the exposure (e.g, LDL 
cholesterol) they relate more strongly to disease outcome (e.g. CHD) than would be seen in an 
observational study or a relatively short term (a few years) RCT of cholesterol reduction4 7. More 
strikingly, an exposure that influences disease risk at a critical period of the lifecourse – as has been 
suggested for vitamin D levels during the pre-adult stage in relation to multiple sclerosis risk – will be 
uncovered by a MR study (since the genetic variants influence vitamin D levels across life), but an 
intervention (or observational study) outside of that time period would not be expected to 
recapitulate this finding8.   
Early MR studies tended to use single genetic variants and focus on a specific risk factor-disease 
association within one study population. More recently the rapid growth in established genotype-
phenotype associations coming from genome wide association studies (GWAS) has led to there 
being large numbers of genetic variants for many exposures and a large number of disease outcomes 
with available GWAS data. In this issue of JAMA a group that have made major contributions to 
applying MR in the cardiovascular drug target context7 report an extensive MR analysis of whether – 
and if so how – abdominal obesity (indexed by waist-to-hip ratio) influences risk of CHD and type II 
diabetes9.They conclude that over and above its association with body mass index (BMI), abdominal 
adiposity has an influence on the risk of both diseases, and that with respect to CHD, triglycerides 
account for much of the elevated risk.   
Publically available GWAS data from consortia were utilised to estimate the effect of abdominal 
adiposity on disease outcomes, in what are known as two-sample MR analysis5. This approach has 
additional assumptions to single-sample studies5, but has the very considerable advantage of 
allowing estimation of the causal effects of a very large array of potential exposures on many disease 
outcomes. A platform, MR-Base, is now available that facilitates rapid two-sample MR interrogation 
of a myriad of such exposure-outcome associations10.  In addition to data from GWAS consortia 
Emdin and colleagues utilised data from UK Biobank, and replicated the estimated causal effects on 
CHD and type II diabetes, and demonstrated that blood pressure is influenced by abdominal 
adiposity whilst a large range of other outcomes are not9. 
Several violations of the assumptions required for reliable application of MR4 are possible, and 
Emdin and colleagues are to be congratulated for attempting to evaluate these, using a series of 
approaches mostly detailed in the online-only supplement to the paper9. Genetic variants may have 
additional (pleiotropic) effects which are not mediated through the exposure – in this case 
abdominal adiposity – that they are being utilised as instruments for. The polygenic risk score was 
shown not to be associated with confounding factors that waist to hip ratio itself was related to in 
UK Biobank, and whilst there may of course be unmeasured confounders the lack of association with 
measured variables is reassuring. Sensitivity analyses with different inclusion criteria for genetic 
variants generated similar findings and an exemplary additional series of tests were applied 
(although a regression-based approach to detect evidence of overall pleiotropy and yield a valid 
causal estimates with relaxed assumptions11  was not utilised).  
In public health terms it has proved difficult to reduce obesity levels through interventions, and the 
same may be true for abdominal adiposity. In this situation intervening on causal mediators can 
reduce disease risk without the underlying factor being changed, which appears to have occurred 
with respect to obesity, where treatment of hypertension, widespread cholesterol lowering and 
other preventative interventions have led to a reduction in cardiovascular mortality whilst obesity 
levels have risen in many countries12. Abdominal adiposity is shown to influence several such 
mediators in the current paper, and triglyceride demonstrated to be potentially important with 
respect to CHD risk. A formal MR mediation analysis could be applied which would more robustly 
quantify the contribution of potentially treatable intermediaries13, and targeting such could have 
important public health benefit. 
In terms of disease prevention the current resource of GWAS studies of particular diseases is 
appropriate, as MR studies based on these indicate causes that could be modified to reduce disease 
risk. However it is often stated that such GWAS can help identify targets for disease treatment. This 
is not necessarily the case, however, since in many cases factors that trigger disease will not be the 
same as those that influence its progression. For example, lung cancer case-control GWAS identified 
genetic variation related to smoking intensity as the top hit, confirming smoking as a cause of lung 
cancer. Once lung cancer has developed, though, smoking cessation is not an effective treatment. A 
recent GWAS of Crohn’s disease prognosis found completely independent genetic predictors of 
disease progression to those that had been identified for disease onset, and the genetic correlation 
between onset and prognosis was negative14. This illustrates what may be a general phenomenon, 
and suggests that to inform identification of treatment targets, and to be able to perform MR 
studies of such, more genetic studies of disease progression and prognosis are required.  
MR is slowly beginning to generate data of clear clinical and public health relevance. Attention to MR 
data might have helped avoid several very expensive late stage clinical trial failures7 and might 
improve prediction of what RCTs will show15 16 (Ference x 2). The conclusion from the first extended 
presentation of MR 15 years ago remains apposite, however: “it is probably fair to say that the 
method offers a more robust approach to understanding the effect of some modifiable exposures on 
health outcomes than does much conventional observational epidemiology. Where possible 
randomized controlled trials remain the final arbiter of the effects of interventions intended to 
influence health, however.”4 
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